U.S. Court of prayers for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Action
Sitagliptin is an active component in JANUVIA ®, JANUMET ® and JANUMET ® XR
Merck( NYSE MRK), known as MSD outside of the United States and Canada, blazoned moment that theU.S. Court of prayers for the Federal Circuit ruled in favor of the company in a patent challenge brought by Mylan Pharmaceuticals,Inc.( now Viatris) related to sitagliptin dihydrogen phosphate, an active component in JANUVIA ®( sitagliptin), JANUMET ®( sitagliptin and metformin hydrochloride) and JANUMET ® XR( sitagliptin and metformin hydrochloride extended- release).
Viatris had challenged validity ofU.S. PatentNo. in an inter partes review before theU.S. Patent Office. On May 7, 2021, the Patent Office issued a decision in Merck’s favor, chancing all challenged claims valid. Viatris appealed that decision to the Court of prayers for the Federal Circuit, which moment affirmed the decision.
Viatris had preliminarily challenged validity of the patent in a case filed in theU.S. District Court for the Northern District of West Virginia. The District Court ruled in favor of Merck in a decision datedSept. 21, 2022.
Moment’s ruling from theU.S. Court of prayers provides JANUVIA, JANUMET and JANUMET XR patent protection through May 2027, which includes six( 6) months of pediatric exclusivity. The company has settled with multiple general companies, furnishing that these general companies can bring their sitagliptin dihydrogen phosphate or sitagliptin- metformin product to the request in May 2026 or earlier under certain circumstances, and their sitagliptin- metformin extended- release product to the request in July 2026 or earlier under certain circumstances.
At Merck, known as MSD outside of the United States and Canada, we’re unified around our purpose We use the power of leading- edge wisdom to save and ameliorate lives around the world. For further than 130 times, we’ve brought stopgap to humanity through the development of important drugs and vaccines. We aspire to be the premier exploration- ferocious biopharmaceutical company in the world – and moment, we’re at the van of exploration to deliver innovative health results that advance the forestallment and treatment of conditions in people and creatures. We foster a different and inclusive global pool and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.